|Titre :||European mapping of harm reduction interventions in prisons|
|Auteurs :||A. TARJAN ; G. HORVATH ; H. STÖVER|
|Type de document :||Rapport|
|Editeur :||Frankfurt am Main : Institut für Suchtforschung (ISFF), 2019|
|Autre Editeur :||Frankfurt am Main : Frankfurt University of Applied Sciences|
|Format :||84 p.|
|Discipline :||MAL (Maladies infectieuses / Infectious diseases)|
Thésaurus TOXIBASEREDUCTION DES RISQUES ; PRISON ; HEPATITE ; VIH ; TUBERCULOSE ; TRAITEMENT DE MAINTENANCE ; NALOXONE ; PREVALENCE ; INTERVENTION ; PREVENTION ; PRODUIT ILLICITE ; INFECTION ; DEPISTAGE
Thésaurus GéographiqueEUROPE ; UNION EUROPEENNE
The Joint Action on HIV and Co-infection Prevention and Harm Reduction (HA-REACT) addresses existing gaps in the prevention of HIV and other co-infections, especially tuberculosis (TB) and viral hepatitis, among people who inject drugs (PWID). The three-year project was launched in late 2015 with core funding by the Health Programme 2014-2020 from European Union (EU). Twenty-two partners representing 18 EU Member States were implementing the project. Additional expertise was provided by 14 collaborating partners, including the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The HA-REACT project has been carried out in three focus countries: Latvia, Lithuania and Hungary. However, materials developed as part of the Joint Action will be of benefit to the entire European Union.
The project's main objectives are:
- to prevent HIV, viral hepatitis and tuberculosis among people who use drugs in Europe.
- to improve countries' capacity to respond to HIV and co-infection risks, and provide harm reduction measures, focusing specifically on PWID.
- to focus on European Union member states where there are obvious barriers to effective and evidence-based interventions, or where such interventions are not sufficiently implemented.
- to encourage the implementation of comprehensive harm reduction in all EU Member States, as an essential strategy to improve the prevention and treatment of HIV, TB and viral hepatitis.
The overall aim of HA-REACT is to significantly contribute to the elimination of HIV and to reduce the number of cases of TB and viral hepatitis among PWID in the European Union by 2020. This objective aligns with strategic action plans issued by the European Union, World Health Organization, UNAIDS and the United Nations Office on Drugs and Crime (UNODC).
|Domaine :||Drogues illicites / Illicit drugs|